<SEC-DOCUMENT>0000912282-25-000059.txt : 20250124
<SEC-HEADER>0000912282-25-000059.hdr.sgml : 20250124
<ACCEPTANCE-DATETIME>20250124212118
ACCESSION NUMBER:		0000912282-25-000059
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250124

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Scinai Immunotherapeutics Ltd.
		CENTRAL INDEX KEY:			0001611747
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-89384
		FILM NUMBER:		25555569

	BUSINESS ADDRESS:	
		STREET 1:		JERUSALEM BIOPARK, 2ND FLOOR
		STREET 2:		HADASSAH EIN KEREM CAMPUS
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			00000
		BUSINESS PHONE:		972-8-9302529

	MAIL ADDRESS:	
		STREET 1:		JERUSALEM BIOPARK, 2ND FLOOR
		STREET 2:		HADASSAH EIN KEREM CAMPUS
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BiondVax Pharmaceuticals Ltd.
		DATE OF NAME CHANGE:	20140624

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STONE DANIEL E.
		CENTRAL INDEX KEY:			0001948744
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	MAIL ADDRESS:	
		STREET 1:		1200 BRICKELL AVENUE, #1470
		CITY:			MIAMI
		STATE:			FL
		ZIP:			33131
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
<headerData>
<submissionType>SCHEDULE 13G/A</submissionType>
<previousAccessionNumber>0001567619-22-018298</previousAccessionNumber>
<filerInfo>
<filer>
<filerCredentials>
<cik>0001948744</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>


</filerInfo>
</headerData>
<formData>
<coverPageHeader>
<amendmentNo>4</amendmentNo>
<securitiesClassTitle>American Depositary Shares, each representing 4,000 Ordinary Shares, no par value</securitiesClassTitle>
<eventDateRequiresFilingThisStatement>12/31/2024</eventDateRequiresFilingThisStatement>
<issuerInfo>
<issuerCik>0001611747</issuerCik>
<issuerName>Scinai Immunotherapeutics Ltd.</issuerName>
<issuerCusip>09073Q203</issuerCusip>
<issuerPrincipalExecutiveOfficeAddress>
<com:street1>Jerusalem BioPark, 2nd Floor</com:street1>
<com:street2>Hadassah Ein Kerem Campus</com:street2>
<com:city>Jerusalem</com:city>
<com:stateOrCountry>L3</com:stateOrCountry>
<com:zipCode>0000000</com:zipCode>
</issuerPrincipalExecutiveOfficeAddress>
</issuerInfo>
<designateRulesPursuantThisScheduleFiled>
<designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
</designateRulesPursuantThisScheduleFiled>
</coverPageHeader>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>Stone Daniel E.</reportingPersonName>
<citizenshipOrOrganization>X1</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>87746</soleVotingPower>
<sharedVotingPower>0</sharedVotingPower>
<soleDispositivePower>87746</soleDispositivePower>
<sharedDispositivePower>0</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>87746</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>9.99</classPercent>
<typeOfReportingPerson>IN</typeOfReportingPerson>
<comments>Based on 3,411,983,584 ordinary shares outstanding as of September 30, 2024, as disclosed by the issuer on November 22, 2024.  Includes 62,400 American Depositary Shares (ADSs) held directly, and 25,346 ADSs issuable upon exercise of pre-funded warrants held by RK Stone Miami LLC (RK).  RK holds 646,442 pre-funded warrants, which may not be exercised if such exercise would result in beneficial ownership by RK, together with its affiliates (which include the reporting person) and certain other persons, of greater than 9.99% of the ordinary shares.  Future issuances of ordinary shares or ADSs by the issuer to third parties are expected to cause additional amounts of pre-funded warrants to become exercisable within the foregoing limitation, without increasing the reporting person's beneficial ownership percentage.</comments>
</coverPageHeaderReportingPersonDetails>
<items>
<item1>
<issuerName>Scinai Immunotherapeutics Ltd.</issuerName>
<issuerPrincipalExecutiveOfficeAddress>Jerusalem BioPark, 2nd Floor, Hadassah Ein Kerem Campus, Jerusalem, Israel, 0000000</issuerPrincipalExecutiveOfficeAddress>
</item1>
<item2>
<filingPersonName>Daniel E. Stone</filingPersonName>
<principalBusinessOfficeOrResidenceAddress>1200 Brickell Avenue, #1470&#13;
Miami, FL 33131</principalBusinessOfficeOrResidenceAddress>
<citizenship>United States</citizenship>
</item2>
<item3>
<notApplicableFlag>Y</notApplicableFlag>
</item3>
<item4>
<amountBeneficiallyOwned>87,746</amountBeneficiallyOwned>
<classPercent>9.99</classPercent>
<numberOfSharesPersonHas>
<solePowerOrDirectToVote>87,746</solePowerOrDirectToVote>
<sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
<solePowerOrDirectToDispose>87,746</solePowerOrDirectToDispose>
<sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
</numberOfSharesPersonHas>
</item4>
<item5>
<notApplicableFlag>Y</notApplicableFlag>
</item5>
<item6>
<notApplicableFlag>Y</notApplicableFlag>
</item6>
<item7>
<notApplicableFlag>Y</notApplicableFlag>
</item7>
<item8>
<notApplicableFlag>Y</notApplicableFlag>
</item8>
<item9>
<notApplicableFlag>Y</notApplicableFlag>
</item9>
<item10>
<notApplicableFlag>N</notApplicableFlag>
<certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
</item10>
</items>
<signatureInformation>
<reportingPersonName>Stone Daniel E.</reportingPersonName>
<signatureDetails>
<signature>/s/ Daniel E. Stone</signature>
<title>Stone Daniel E.</title>
<date>01/24/2025</date>
</signatureDetails>
</signatureInformation>
</formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
